Renaissance Technologies’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-6,038
Closed -$59K – 4586
2022
Q3
$59K Sell
6,038
-1,974
-25% -$45.9K ﹤0.01% 3715
2022
Q2
$271K Buy
8,012
+2,074
+35% +$96.9K ﹤0.01% 3514
2022
Q1
$420K Buy
5,938
+5,860
+7,513% +$1.08M ﹤0.01% 3293
2021
Q4
$24K Buy
+78
New +$48.9K ﹤0.01% 3835
2021
Q1
– Sell
-302
Closed -$426K – 3864
2020
Q4
$426K Buy
302
+277
+1,108% +$567K ﹤0.01% 2891
2020
Q3
$98K Buy
+25
New +$113K ﹤0.01% 3217
2020
Q2
– Sell
-11
Closed -$37K – 3879
2020
Q1
$37K Sell
11
-197
-95% -$1.86M ﹤0.01% 3348
2019
Q4
$2.02M Buy
+208
New +$1.77M ﹤0.01% 2326

Other funds holding BXRX

Renaissance Technologies's BXRX Position: Q4 2022 in Review

Renaissance Technologies sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2022, closing a stake of 6,038 shares — an estimated $59K sold.

Renaissance Technologies first reported a position in BXRX in Q4 2019 and held it in 8 quarters. The position peaked at $2.02M in Q4 2019. 10 funds tracked by Wall St. Rank hold BXRX as of Q4 2022.

  • Renaissance Technologies reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Renaissance Technologies sold 6,038 Baudax Bio, Inc. Common Stock shares in Q4 2022, an estimated $59K.
  • Renaissance Technologies first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 8 quarters.
  • Renaissance Technologies's Baudax Bio, Inc. Common Stock position peaked at $2.02M in Q4 2019.
  • 10 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2022.

Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.